ID   OVMIU
AC   CVCL_3112
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03151882
DR   BioSample; SAMN03472489
DR   CCLE; OVMIU_OVARY
DR   Cell_Model_Passport; SIDM00465
DR   Cosmic; 1995608
DR   Cosmic-CLP; 1240200
DR   DepMap; ACH-002183
DR   GDSC; 1240200
DR   GEO; GSM827252
DR   GEO; GSM1670324
DR   JCRB; JCRB1049
DR   JCRB; NIHS0302
DR   JCRB; NIHS0344
DR   LINCS_LDP; LCL-1526
DR   Wikidata; Q54937032
RX   PubMed=20143388;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
WW   http://cellbank.nibiohn.go.jp/legacy/cellbank/qualitycontrol/identification/summary.htm
WW   http://iclac.org/wp-content/uploads/Cross-Contaminations_v9_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a OVSAYO derivative (PubMed=20143388).
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00341.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Heterozygous for TP53 p.Arg249Met (c.746G>T) (from parent cell line).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.26%; Native American=0.2%; East Asian, North=75.07%; East Asian, South=23.44%; South Asian=1.02%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0302; true.
CC   Discontinued: JCRB; NIHS0344; true.
ST   Source(s): Cosmic-CLP; JCRB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,11
ST   D16S539: 9,10
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   TH01: 7
ST   TPOX: 9,11
ST   vWA: 17,18
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_3115 ! OVSAYO
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-07-19; Version: 23
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//